Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, is pleased to report that trading continues to be very strong.

Sales in the nine months ended 30 September 2009 were £21.4m, up 44% from the £14.9m achieved in the same period in 2008, reflecting the positive sales trends reported at the time of the Company's interim results. Sales by Alliance of Buccastem® and Timodine®, the two brands acquired by the Company in August 2009, have been in line with management's expectations since their acquisition.

If the recent strong trading performance continues for the remainder of the year, the Board expects the Group's profit before tax for 2009 to significantly exceed its previous expectations.

The Company intends to provide a further trading update for the full year in January 2010.

For further information:

Alliance Pharma plc                  + 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk

Buchanan Communications       + 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic / Jennie Spivey

Numis Securities Limited           + 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Brent Nabbs
Corporate Broking: David Poutney